Impact of patients’ and disease characteristics on treatment response and overall survival since the beginning of combined immunotherapy

	Total n = 35	Responder n = 15	Non-Responder n = 20	Response P value	Overall survival P value
TMB [Mut/Mb]
> 23	6	6	0	0.0021*	0.062
≤ 23	24	6	18	0.0021*	0.062
ctDNA [copies/ml] detection5
Not detectable	14	10	4	0.0111*	0.0062*
Detectable	18	4	14	0.0111*	0.0062*
ctDNA [copies/ml] increase5
Not increasing	20	12	8	0.0081*	0.032*
Increasing	11	1	10	0.0081*	0.032*
Cell-free DNA [ng/ml]6
Decrease > 50%	7	5	2	0.0223*	0.0054*
Stable	15	7	8
Increase > 50%	9	1	8
LDH baseline elevated
No	21	11	10	0.2961	0.0012*
Yes	14	4	10	0.2961	0.0012*
Targeted therapy before
No	25	12	13	0.4581	0.0012*
Yes	10	3	7	0.4581	0.0012*
Sex
Male	19	11	8	0.0871	0.0052*
Female	16	4	12	0.0871	0.0052*
Liver metastasis baseline
No	25	14	11	0.0221*	0.0132*
Yes	10	1	9	0.0221*	0.0132*
PD-L1 Expression
≥ 1%	10	6	4	0.0801	0.7722
< 1%	11	2	9	0.0801	0.7722

* significant (in bold).

¹Exact Test of Fisher

²Log rank test

³Exact Chi-Square Test for Trend (Monte Carlo Simulation)

⁴Log rank test for Trend

⁵ctDNA measured by tumor-specific variant [copies/ml plasma] at first follow-up after start of combined immunotherapy

⁶Cell-free DNA [ng/ml plasma] at first follow-up after start of combined immunotherapy